Carregant...
Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal
In the field of rare diseases (RDs), the evidence standard is often lower than that required by health technology assessment (HTA) and payer authorities. In this commentary, we propose that appropriate economic evaluation for rare disease treatments should be initially informed by cost-of-illness (C...
Guardat en:
| Publicat a: | Int J Environ Res Public Health |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7908548/ https://ncbi.nlm.nih.gov/pubmed/33530652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijerph18031101 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|